CD274 and triple-negative breast carcinoma: Antitumor efficacy was tested in MC38-hPD-L1 syngeneic tumors, HCC827 non-small cell lung cancer (NSCLC) xenografts, and MDA-MB-231 triple-negative breast cancer (TNBC) xenografts.<h4>Results</h4>IMM2510 bound PD-L1, VEGF-A, VEGF-B, and PlGF with high affinity, and blocked both PD-1/PD-L1 and VEGF/VEGFR interactions.